Song J, Shen H, Li J, Huang Z. et al. 2002. [Effects of metformin on the plasminogen activator system, endocrine, metabolic proﬁles in patients with polycystic ovary syndrome and clomiphene resistant cases]. Zhonghua Fu Chan Ke Za Zhi, 37:86–9. Spiegelman BM, Flier JS. 1996. Adipogenesis and obesity: rounding out the big picture. Cell, 87:377–89. Stephens JM, Pilch PF. 1995. The metabolic regulation and vesicular transport of GLUT4, the major insulin-responsive glucose transporter. Endocr Rev, 16:529–46. Steppan CM, Bailey ST, Bhat S, et al. 2001. The hormone resistin links obesity to diabetes. Nature, 409:307–12. Swenson TL. 1991. The role of the cholesteryl ester transfer protein in lipoprotein. metabolism. Diabetes Metab Rev, 7:139–53. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. 2000. Evidence for as- sociation between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol, 20:2414–21. Tarkun I, Canturk Z, Arslan BC, et al. 2004. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J, 51:467–72. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. 2004. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 53:2169–76. Tolino A, Gambardella V, Caccavale C, et al. 2005. Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol, 119:87–93. Velazquez EM, Mendoza SG, Wang P, et al. 1997. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism, 46:454–7. Vgontzas AN, Legro RS, Bixler EO, et al. 2001. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness:role of insulin resistance. J Clin Endocrinol Metab, 86:517–20. Vrbikova J, Cifkova R, Jirkovska A, et al. 2003. Cardiovascular risk fac- tors in young Czech females with polycystic ovary syndrome. Hum Reprod, 18:980–4. Cardiometabolic aspects of POCS Waterworth DM, Bennett ST, Gharani N, et al. 1997. Linkage and associa- tion of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet, 349:986–90. Wild RA, Painter PC, Coulson PB, et al. 1985. Lipoprotein lipid concentra- tions and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 61:946–51. Wild S, Pierpoint T, Jacobs H, et al. 2000a. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb), 3:101–105. Wild S, Pierpoint T, McKeigue P, et al. 2000b. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up:a retrospective cohort study. Clin Endocrinol (Oxf), 52:595–600. Yildirim B, Sabir N, et al. 2003. Relation of intra-abdominal fat distribu- tion to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril, 79:1358–64. Yildiz BO, Haznedaroglu IC, Kirazli S, et al. 2002. Global ﬁbrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a pro- thrombotic state. J Clin Endocrinol Metab, 87:3871–5. Yu JG, Javorschi S, Hevener AL, et al. 2002. The effect of thiazolidinedio- nes on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes, 51:2968–74. Yu YH, Ginsberg HN. 2005. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res, 96:1042–52. Zavaroni I, Coruzzi P, Bonini L, et al. 1995. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am J Hypertens, 8:855–8. Zhang LH, Rodriguez H, Ohno S, et al. 1995. Serine phosphorylation of human P450c17 increases 17,20-lyase activity:implications for adre- narche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A, 92:10619–23. Zimmermann S, Phillips RA, Dunaif A, et al. 1992. Polycystic ovary syn- drome:lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab, 75:508–13. Vascular Health and Risk Management 2007:3(1) 63